ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向治疗和生物治疗安全性的共识文件:感染病学视角(细胞表面受体及相关信号通路)
本文为 ESCMID 免疫功能受损宿主感染研究组(ESGICH)共识文件的一部分,从感染病学视角综述靶向细胞表面受体及相关信号通路的抗肿瘤治疗的安全性,并据此提出预防建议。VEGF 靶向药物与感染风险增加相关,而抗 EGFR 单抗可致中性粒细胞减少及严重皮疹继发皮肤软组织感染,应使用全身抗生素预防。
要点
- VEGF 靶向药物(贝伐珠单抗、阿柏西普)与感染风险有意义增加相关,不推荐普遍预防性抗感染。
- 抗 EGFR 单抗(西妥昔单抗、帕尼单抗)可致中性粒细胞减少,严重丘疹脓疱性皮疹时应使用多西环素或米诺环素预防继发感染。
- 抗 ErbB2/HER2 单抗及 ErbB 受体酪氨酸激酶抑制剂感染风险低于传统化疗。
核心结论
- 除 VEGF 靶向药物外,所综述治疗的总体感染风险似乎较低。
研究设计与样本
- ESCMID 免疫功能受损宿主感染研究组(ESGICH)共识文件,通过计算机检索 Medline 对各药物或治疗类别相关 MeSH 主题词进行文献综述。
主要发现
- VEGF 靶向药物(贝伐珠单抗和阿柏西普)与感染风险有意义增加相关,可能由药物诱导的中性粒细胞减少所致。
- VEGF 酪氨酸激酶抑制剂(索拉非尼或舒尼替尼)似乎不显著影响宿主对感染的易感性。
- 抗 EGFR 单克隆抗体(西妥昔单抗或帕尼单抗)可致中性粒细胞减少,并在严重丘疹脓疱性皮疹时继发皮肤软组织感染。
- 抗 ErbB2/HER2 单克隆抗体(曲妥珠单抗和帕妥珠单抗)及 ErbB 受体酪氨酸激酶抑制剂(包括拉帕替尼或来那替尼等双 EGFR/ErbB2 抑制剂)感染风险低于传统化疗,推测与药物诱导的中性粒细胞减少发生减少有关。
关键数值与推荐
- VEGF 靶向药物:不推荐普遍使用抗感染预防(原文未给出推荐强度分级)。
- VEGF 酪氨酸激酶抑制剂:不推荐普遍抗感染预防(原文未给出推荐强度分级)。
- 抗 EGFR 单抗:严重丘疹脓疱性皮疹时应使用全身抗生素(多西环素或米诺环素)预防继发皮肤软组织感染(原文未给出推荐强度分级)。
- 抗 EGFR 单抗:无法就抗病毒、抗真菌或抗肺孢子菌预防的获益建立推荐(原文未给出推荐强度分级)。
临床怎么用
- VEGF 靶向药物治疗者不推荐普遍抗感染预防。
- VEGF 酪氨酸激酶抑制剂治疗者不推荐普遍抗感染预防。
- 抗 EGFR 单抗治疗出现严重丘疹脓疱性皮疹时,应使用多西环素或米诺环素预防继发皮肤软组织感染。
- 抗 EGFR 单抗治疗者是否进行抗病毒、抗真菌或抗肺孢子菌预防,尚无推荐可建立。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies. AIMS: To review, from an infectious diseases perspective, the safety profile of therapies targeting cell surface receptors and associated signaling pathways among cancer patients and to suggest preventive recommendations. SOURCES: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Vascular endothelial growth factor (VEGF)-targeted agents (bevacizumab and aflibercept) are associated with a meaningful increase in the risk of infection, likely due to drug-induced neutropaenia, although no clear benefit is expected from the universal use of anti-infective prophylaxis. VEGF tyrosine kinase inhibitors (i.e. sorafenib or sunitinib) do not seem to significantly affect host's susceptibility to infection, and universal anti-infective prophylaxis is not recommended either. Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab or panitumumab) induce neutropaenia and secondary skin and soft tissue infection in cases of severe papulopustular rash. Systemic antibiotics (doxycycline or minocycline) should be administered to prevent the latter complication, whereas no recommendation can be established on the benefit from antiviral, antifungal or anti-Pneumocystis prophylaxis. A lower risk of infection is reported for anti-ErbB2/HER2 monoclonal antibodies (trastuzumab and pertuzumab) and ErbB receptor tyrosine kinase inhibitors (including dual-EGFR/ErbB2 inhibitors such as lapatinib or neratinib) compared to conventional chemotherapy, presumably as a result of the decreased occurrence of drug-induced neutropaenia. IMPLICATIONS: With the exception of VEGF-targeted agents, the overall risk of infection associated with the reviewed therapies seems to be low.
引用
- Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). Clin Microbiol Infect. 2018. PMID: 29426804. doi:10.1016/j.cmi.2017.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。